Intellia Therapeutics Announces Executive and Board Changes
Ticker: NTLA · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1652130
Sentiment: neutral
Topics: executive-changes, board-changes, leadership
Related Tickers: NTLA
TL;DR
Intellia shakes up leadership: new CEO, CMO, and board member appointed.
AI Summary
Intellia Therapeutics, Inc. announced on April 10, 2024, changes in its executive and board leadership. Dr. John Leonard has been appointed as the new Chief Executive Officer, and Mr. Glenn Pierce has been appointed as Chief Medical Officer. Additionally, Ms. Michelle Robertson has joined the Board of Directors.
Why It Matters
These leadership changes could signal a new strategic direction for Intellia Therapeutics as it advances its gene editing therapies.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, impacting investor confidence.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- Dr. John Leonard (person) — Appointed Chief Executive Officer
- Mr. Glenn Pierce (person) — Appointed Chief Medical Officer
- Ms. Michelle Robertson (person) — Joined Board of Directors
- April 10, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new CEO of Intellia Therapeutics?
Dr. John Leonard has been appointed as the new Chief Executive Officer.
What is the new role for Mr. Glenn Pierce?
Mr. Glenn Pierce has been appointed as the Chief Medical Officer.
Who has joined the Board of Directors at Intellia Therapeutics?
Ms. Michelle Robertson has joined the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 10, 2024.
What is the principal executive office address for Intellia Therapeutics?
The address of the Principal Executive Offices is 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-15 16:21:29
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
Filing Documents
- ntla-20240410.htm (8-K) — 36KB
- ntla-ex99_1.htm (EX-99.1) — 28KB
- img149557450_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-044424.txt ( ) — 191KB
- ntla-20240410.xsd (EX-101.SCH) — 24KB
- ntla-20240410_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: April 15, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President